Stock BPTH BIO-PATH HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
3.24 USD +6.23% Intraday chart for Bio-Path Holdings, Inc. -6.36% -65.01%
Apr. 15 Bio-Path Holdings, Inc. Expands Global Patent Portfolio CI
Apr. 05 North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bio-Path Holdings Expands Global Patent Portfolio
AQ
Bio-Path Holdings, Inc. Expands Global Patent Portfolio
CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited
DJ
Bio-Path Holdings Provides 2024 Clinical and Operational Update
AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K
PU
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024
Bio-Path Holdings Reports Full Year 2023 Financial Results
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
AQ
Reverse Split: 1 of 20
FA
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory Relapsed Lymphoma and Refractory Relapsed Chronic Lymphocytic Leukemia Patients
AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory, Relapsed Acute Myeloid Leukemia
AQ
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
AQ
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BPTH Stock
  4. News Bio-Path Holdings, Inc.